Current practice versus willingness to enroll in clinical trials: Paradox among vascular neurologists about treatment for acute ischemic stroke

Stroke

Volumn 41, Issue 9, 2010, Pages 2038-2043

  El Khoury, Ramy ^a   Fisher, Marc ^b   Savitz, Sean I ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b University of Massachusetts   (United States)

Author keywords

acute ischemic stroke; clinical trial design; intra arterial therapy; neuroimaging; vascular neurologist

Indexed keywords

PLACEBO; TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

ACUTE ISCHEMIC STROKE; ADULT; ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; HEALTH SURVEY; HUMAN; IMAGING; INTERNET; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL SOCIETY; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYMPTOM; TREATMENT DURATION; UNIVERSITY; ATTITUDE TO HEALTH; CLINICAL TRIAL (TOPIC); FIBRINOLYTIC THERAPY; HEALTH CARE SURVEY; PROCEDURES; STROKE; TIME; TREATMENT OUTCOME; UNITED STATES;

CLINICAL TRIALS AS TOPIC; FEMALE; FIBRINOLYTIC AGENTS; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; UNITED STATES;

EID: 77956404250     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.586511     Document Type: Article

References (22)

1. Heron H. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57:1-104.
2. Helgason C, Wolf P. American Heart Association Prevention Conference IV: prevention and rehabilitation of stroke. Stroke. 1997;28:1498-1500. (Pubitemid 27300693)
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
4. Kidwell S, Jahan R. Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE). Clinical trial identifier NCT00389467. Available at: http://clinicaltrials.gov/ct2/show/NCT00389467?term= NCT00094588&rank=1. Last accessed July 13, 2010.
5. Khatri P, Hill MD, Palesch YY, Spilker J, Jauch EC, Carrozzella JA, Demchuk AM, Martin R, Mauldin P, Dillon C, Ryckborst KJ, Janis S, Tomsick TA, Broderick JP; Interventional Management of Stroke III Investigators. Methodology of the Interventional Management of Stroke III Trial. Int J Stroke. 2008;3:130-137. (Pubitemid 351566847)
6. Wasiewski WW, Johnston KC. Clinical trials, devices, unproven treatments, and clinical equipoise. Stroke. 2009;40:e441-e442.
7. Mishra NK, Albers GW, Davis SM, Donnan GA, Furlan AJ, Hacke W, Lees KR. Mismatch-based delayed thrombolysis: a meta-analysis. Stroke. 2010;41:e25-e33.
8. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Kakuda W, Lansberg MG, Shuaib A, Coplin W, Hamilton S, Moseley M, Marks MP; DEFUSE Investigators. Magnetic resonance
9. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66-73.
10. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, Kaste M, Lipka LJ, Pedraza S, Ringleb PA, Rowley HA, Schneider D, Schwamm LH, Leal JS, Söhngen M, Teal PA, Wilhelm-Ogunbiyi K, Wintermark M, Warach S. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2008;8:141-150.
11. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W; DEDAS Investigators. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37:1227-1231.
12. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM; EPITHET investigators. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008; 7:299-309.
13. Kakuda W, Abo M. Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke\MRI-based decision making. Brain Nerve. 2008;60:1173-1180.
14. Lundbeck A S. Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4). ClinicalTrials.gov identifier: NCT00856661. Available at: http://clinicaltrials.gov/ct2/show/NCT00856661?term = NCT00856661&rank= 1. Last accessed July 13, 2010.
15. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
16. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the Expansion of American Heart Association/American Stroke Association. Stroke. 2009;40:2945-2948.
17. Bose A, Henkes H, Alfke K, Mayer TE, Berlis A, Branca V, Po Sit S. The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am JNeuroradiol. 2008;29:1409-1413.
18. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuja A, Callahan F, Clark WM, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
19. Broderick J. The Interventional Management of Stroke Study Investigators: combined intravenous and intra-arterial recanalization for acute ischemic stroke. Stroke. 2004;35:904-911.
20. Katz JM, Gobin YP. Merci Retriever in acute stroke treatment. Expert Rev Med Devices. 2006;3:273-280.
21. Cook C, Heath F, Thompson RL. A meta-analysis of response rates in web-or Internet-based surveys. Educational and Psychological Measurement. 2000;60:821.
22. Moskowitz A, Chan YF, Bruns J, Levine SR. Emergency physician and stroke specialist beliefs and expectations regarding telestroke. Stroke. 2010;41:805-809.